Drug
Lifitegrast clinical trials
Also written Xiidra and SAR 1118.
- studies test it
- 25
- open now
- 2
- in phase 3
- 5
- first study started
- 2009
Keep track of what changes. Save the lifitegrast studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
25 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 6 |
| 2022 | 3 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 2
- Phase 2
- 3
- Phase 3
- 5
- Phase 4
- 14
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 14
Shire (6) · Bausch & Lomb Incorporated (2) · University of Alabama at Birmingham (2) · Hoffmann-La Roche (1) · Qilu Pharmaceutical Co., Ltd. (1) · University of Waterloo (1) · State University of New York College of Optometry (1) · Richard W Yee, MD (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lifitegrast is read from its arms, and is right about nine times in ten.
Testing it · 25
- Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal MicroscopyNot yet recruitingPhase 4Toyos ClinicNCT07560735Written as Lifitegrast Ophthalmic Solution 5.0% (Xiidra)
- This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry EyeNot yet recruitingPhase 4Pittsburgh Research InstituteNCT07490535Written as (Xiidra®) Lifitegrast Ophthalmic Solution 5.0%
- A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory TreatmentCompletedPhase 4Hoffmann-La RocheNCT07025811Written as Xiidra®
- A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseCompletedPhase 2Bausch & Lomb IncorporatedNCT07128628Written as Lifitegrast/Perfluorohexyloctane Fixed Dose Combination
- A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye DiseaseWithdrawnPhase 3Bausch & Lomb IncorporatedNCT07111013Written as Lifitegrast/perfluorohexyloctane (PFHO)
- Lifitegrast Eye Drops in Healthy Subjects：Phase I StudyCompletedPhase 1Qilu Pharmaceutical Co., Ltd.NCT07040826Written as Xiidra
- The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens WearersCompletedPhase 4University of WaterlooNCT04297618Written as Xiidra
- Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens WearersCompletedPhase 4State University of New York College of OptometryNCT05505292Written as Lifitegrast 5% Ophthalmic Solution
- The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host DiseaseCompletedEarly Phase 1Richard W Yee, MDNCT04792580Written as Lifitegrast 5% Ophthalmic Solution
- Ocular Inflammation in Cataract Patients and Response to Treatment With XiidraWithdrawnPhase 4Bucci Laser Vision InstituteNCT04120987Written as Lifitegrast 5% Ophthalmic Solution
- Treatment Regimens in Meibomian Gland DysfunctionCompletedPhase 4Tauber Eye CenterNCT05594745Written as Lifitegrast Ophthalmic
- The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) StudyCompletedPhase 4Research Insight LLCNCT04669561Written as Lifitegrast 5% Ophthalmic Solution
- Efficacy of Xiidra in Dry Eye Disease After Collagen Cross LinkingStatus unknownPhase 4Benha UniversityNCT05045053Written as Xiidra 5% Ophthalmic Solution
- A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)CompletedPhase 2ShireNCT00926185Written as Lifitegrast
- A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry EyeCompletedPhase 3ShireNCT01743729Written as Lifitegrast
- A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)CompletedPhase 3ShireNCT02284516Written as Lifitegrast
- Safety Study of Lifitegrast to Treat Dry EyeCompletedPhase 3ShireNCT01636206Written as Lifitegrast
- Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)CompletedPhase 3ShireNCT01421498Written as Lifitegrast
- Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic ConjunctivitisCompletedPhase 2ShireNCT00882687Written as Lifitegrast
- Effect of Lifitegrast 5% on Tear Film MarkersWithdrawnPhase 4Weill Medical College of Cornell UniversityNCT03952481Written as Lifitegrast 5% Ophthalmic Solution
See all 25 studies that test lifitegrast →
As the comparator · 5 — what is tested is compared with lifitegrast
- A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye DiseaseCompletedPhase 1/2AbbVieNCT04030962Written as Lifitegrast 5% Ophthalmic Solution
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye DiseaseCompletedPhase 2Surface Ophthalmics, Inc.NCT04734197Written as Lifitegrast 5% Ophthalmic Solution
- An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease ChamberCompletedPhase 2Aldeyra Therapeutics, Inc.NCT05102409Written as Xiidra® (5% lifitegrast ophthalmic solution)
- Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 DaysStatus unknownPhase 4Toyos ClinicNCT04172961Written as Lifitegrast
- Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye DiseaseTerminatedPhase 4Eye Surgeons of IndianaNCT04413253Written as Lifitegrast 5% Ophthalmic Solution
Codes
What other systems call lifitegrast · ClinicalTrials.gg INT006147
- MeSH (NLM) C575157lifitegrastConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 038E5L962WLIFITEGRASTConfirmed FDA, NLM, Wikidata
- RxNorm 1801820Confirmed FDA, Wikidata
- Wikidata Q23044263lifitegrastConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175726LifitegrastOne source FDA
- DrugBank DB11611One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C575157 | lifitegrast | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 038E5L962W | LIFITEGRAST | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1801820 | — | Confirmed FDA, Wikidata |
| Wikidata | Q23044263 | lifitegrast | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175726 | Lifitegrast | One source FDA |
| DrugBank | DB11611 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.